National Academy of Development and Strategy, Renmin University of China, No. 59 Zhongguancun Street, Haidian District, Beijing, 100872, China.
College of Nursing and Rehabilitation, North China University of Science and Technology, No.21 Bohai Road, Caofeidian District, Tangshan, 063210, Hebei, China.
Support Care Cancer. 2019 Apr;27(4):1171-1180. doi: 10.1007/s00520-019-04667-7. Epub 2019 Feb 2.
Previous meta-analyses have examined the prevalence of sexual dysfunction among women with cancer, but there is no breast cancer (BC)-specific study. We therefore conducted a meta-analysis to examine the prevalence and severity of female sexual dysfunction (FSD) in women with BC.
We searched PubMed, Embase, Cochrane Library, CNKI, WanFang Data, and VIP for relevant studies published between April 2000 and January 2017. Data were extracted from studies which assessed FSD prevalence and sexual function in women with BC using the female sexual function index (FSFI). Meta-analyses were performed by pooling the prevalence rates of FSD and total FSFI scores. Meta regression was performed to explore the sources of heterogeneity.
We selected 19 published studies involving a total of 2684 women with BC. In this study population, overall FSD prevalence was 73.4% (95% confidence interval (CI) 64.0%, 82.8%), and the total FSFI score was 19.28 (95% CI 17.39, 21.16). Among Asian, American, and European women with BC, there were significant differences in FSD prevalence (P < 0.001), and there was marginally significant difference (P = 0.07) in sexual function between these groups. There was also a marginally significant difference between individuals from mainland China and from other countries in FSD prevalence (P = 0.06) and FSFI score (P = 0.07).
Overall, women with BC have high FSD prevalence and low sexual function. American women with BC have a higher average FSD prevalence and lower average sexual function than Asian women with BC. The FSD prevalence in women with BC in mainland China was slightly higher than in other countries.
先前的荟萃分析研究了癌症女性患者性功能障碍的流行情况，但没有专门针对乳腺癌（BC）的研究。因此，我们进行了一项荟萃分析，以评估 BC 女性患者的女性性功能障碍（FSD）的流行率和严重程度。
我们检索了 PubMed、Embase、Cochrane 图书馆、中国知网（CNKI）、万方数据和维普（VIP），以获取 2000 年 4 月至 2017 年 1 月期间发表的相关研究。使用女性性功能指数（FSFI）评估 BC 女性患者的 FSD 流行率和性功能，从研究中提取数据。通过汇总 FSD 流行率和总 FSFI 评分进行荟萃分析。进行荟萃回归分析以探究异质性的来源。
我们选择了 19 项已发表的研究，共纳入 2684 名 BC 女性患者。在该研究人群中，总体 FSD 流行率为 73.4%（95%置信区间 64.0%，82.8%），总 FSFI 评分为 19.28（95%置信区间 17.39，21.16）。亚洲、美洲和欧洲的 BC 女性患者之间，FSD 流行率存在显著差异（P < 0.001），且这些群体之间的性功能存在边际显著差异（P = 0.07）。中国大陆与其他国家的 BC 女性患者之间的 FSD 流行率（P = 0.06）和 FSFI 评分（P = 0.07）也存在边际显著差异。
总体而言，BC 女性患者的 FSD 流行率较高，性功能较低。与亚洲 BC 女性患者相比，美国 BC 女性患者的平均 FSD 流行率较高，平均性功能较低。中国大陆 BC 女性患者的 FSD 流行率略高于其他国家。
